Can I read A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids on EtoBox?

A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids by Yao Teng; Zixuan Zhao; Farah Tasnim; Xiaozhong Huang; Hanry Yu is a Engineering article available to read on EtoBox.

What is A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids about?

Nonalcoholic fatty liver disease (NAFLD) is a significant liver disease without approved therapy, lacking human NAFLD models to aid drug development. Existing models are either under-performing or too complex to allow robust drug screening. Here we have developed a 100-well drug testing platform with improved HepaRG organoids formed with uniform size distribution, and differentiated in situ in a perfusion microfluidic device, SteatoChip, to recapitulate major NAFLD features. Compared with the pre-differentiated spheroids, the in situ differentiated HepaRG organoids with perfusion experience well-controlled chemical and mechanical microenvironment, and 3D cellular niche, to exhibit enhanced hepatic differentiation (albumin cells ratio: 66.2% in situ perfusion vs 46.1% pre-differentiation), enriched and uniform hepatocyte distribution in organoids, higher level of hepatocyte functions (5.2 folds in albumin secretion and 7.6 folds in urea synthesis), enhanced cell polarity and bile canaliculi structures. When induced with free fatty acid (FFA), cells exhibit significantly higher level of lipid accumulation (6.6 folds for in situ perfusion vs 4.4 folds for pre-differentiation), altered

Who reads A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids?

Author

Yao Teng; Zixuan Zhao; Farah Tasnim; Xiaozhong Huang; Hanry Yu

Publisher

Elsevier BV

Published

2021

Language

EN

Field

Engineering (Physical Sciences)